M.B. Atkins

530 total citations
22 papers, 360 citations indexed

About

M.B. Atkins is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, M.B. Atkins has authored 22 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in M.B. Atkins's work include Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (7 papers) and Renal cell carcinoma treatment (5 papers). M.B. Atkins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (7 papers) and Renal cell carcinoma treatment (5 papers). M.B. Atkins collaborates with scholars based in United States, United Kingdom and France. M.B. Atkins's co-authors include James W. Mier, Mark S. Klempner, Richard Noring, Charles A. Dinarello, Herbert Tilg, Leland Shapiro, J W Mier, Anthony A. Rayner, Michael Hawkins and Rasim Gucalp and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

M.B. Atkins

21 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.B. Atkins United States	9	183	156	87	70	38	22	360
Strieter Rm United States	7	118 0.6×	136 0.9×	42 0.5×	80 1.1×	34 0.9×	7	402
Shuzi Owens United States	9	177 1.0×	112 0.7×	152 1.7×	92 1.3×	23 0.6×	14	498
Ajay Bapna India	10	118 0.6×	64 0.4×	80 0.9×	65 0.9×	30 0.8×	38	363
Kikkie Poels Netherlands	9	157 0.9×	134 0.9×	33 0.4×	62 0.9×	31 0.8×	11	331
Carolyn Quinn United States	6	224 1.2×	110 0.7×	183 2.1×	168 2.4×	21 0.6×	8	505
Stephan Baldus Germany	9	65 0.4×	167 1.1×	71 0.8×	100 1.4×	21 0.6×	29	390
Silvia Tartari Italy	8	220 1.2×	392 2.5×	52 0.6×	147 2.1×	47 1.2×	18	570
Grażyna Wróbel Poland	11	179 1.0×	70 0.4×	111 1.3×	73 1.0×	20 0.5×	29	551
Alain Grenier France	6	131 0.7×	174 1.1×	46 0.5×	107 1.5×	30 0.8×	6	381
Danniele G. Holanda United States	10	53 0.3×	100 0.6×	75 0.9×	94 1.3×	14 0.4×	19	357

Countries citing papers authored by M.B. Atkins

Since Specialization

Citations

This map shows the geographic impact of M.B. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.B. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.B. Atkins more than expected).

Fields of papers citing papers by M.B. Atkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.B. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.B. Atkins. The network helps show where M.B. Atkins may publish in the future.

Co-authorship network of co-authors of M.B. Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of M.B. Atkins. A scholar is included among the top collaborators of M.B. Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.B. Atkins. M.B. Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atkins, M.B., Sandra J. Lee, Bartosz Chmielowski, et al.. (2025). DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.. Journal of Clinical Oncology. 43(16_suppl). 9506–9506.

Agarwal, Neeraj, James Brugarolas, Pooja Ghatalia, et al.. (2024). Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Annals of Oncology. 35(12). 1148–1156. 6 indexed citations

McDermott, David F., Thomas E. Hutson, Elena Verzoni, et al.. (2024). 1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study. Annals of Oncology. 35. S1021–S1021. 1 indexed citations

Choueiri, Toni K., M.B. Atkins, Tracy L. Rose, et al.. (2018). A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy. Annals of Oncology. 29. viii402–viii403. 5 indexed citations

Atkins, M.B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2016). Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Annals of Oncology. 27. vi266–vi266. 26 indexed citations

Kluger, Harriet M., Mario Sznol, Margaret K. Callahan, et al.. (2014). Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel). Annals of Oncology. 25. iv374–iv374. 17 indexed citations

McDermott, David F., Harriet M. Kluger, Mario Sznol, et al.. (2014). Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial. Annals of Oncology. 25. iv375–iv375. 6 indexed citations

McDermott, David F., Charles G. Drake, Mario Sznol, et al.. (2012). Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC). Annals of Oncology. 23. ix258–ix259. 2 indexed citations

Schutz, Fabio A., Kathryn P. Gray, Mark M. Pomerantz, et al.. (2011). Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study.. Journal of Clinical Oncology. 29(15_suppl). 4506–4506. 1 indexed citations

10.

Avigan, David, Jacalyn Rosenblatt, Baldev Vasir, et al.. (2010). Vaccination with DC/RCC fusions following cytoreductive nephrectomy.. Journal of Clinical Oncology. 28(15_suppl). 2511–2511. 1 indexed citations

11.

Waldman, F., Ritu Roydasgupta, Tobias Klatte, et al.. (2008). Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders. Journal of Clinical Oncology. 26(15_suppl). 5043–5043. 6 indexed citations

12.

Bower, Mark, Thomas Powles, Sophie Williams, et al.. (2007). Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease. Journal of Clinical Oncology. 25(18_suppl). 8049–8049. 1 indexed citations

13.

Curiel‐Lewandrowski, Clara & M.B. Atkins. (2001). Immunotherapeutic approaches for the treatment of malignant melanoma.. PubMed. 2(11). 1553–63. 6 indexed citations

14.

Trehu, Elizabeth, J W Mier, Jon S. Dubois, et al.. (1996). Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.. PubMed. 2(8). 1341–51. 14 indexed citations

15.

Tilg, Herbert, M.B. Atkins, Charles A. Dinarello, & James W. Mier. (1995). Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. Cytokine. 7(7). 734–739. 19 indexed citations

16.

Tilg, Herbert, Leland Shapiro, Edouard Vannier, et al.. (1994). Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.. The Journal of Immunology. 152(6). 3189–3198. 18 indexed citations

17.

Tilg, Herbert, Leland Shapiro, M.B. Atkins, Charles A. Dinarello, & J W Mier. (1993). Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.. The Journal of Immunology. 151(6). 3299–3307. 23 indexed citations

18.

Klempner, Mark S., Richard Noring, James W. Mier, & M.B. Atkins. (1990). An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 Immunotherapy. New England Journal of Medicine. 322(14). 959–965. 120 indexed citations

19.

Abrams, Jeffrey S., Anthony A. Rayner, P H Wiernik, et al.. (1990). High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 82(14). 1202–1206. 57 indexed citations

20.

Ryan, T. J., M.B. Atkins, J W Mier, & E. M. Berkman. (1989). Lymphokine‐activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure. Transfusion. 29(6). 491–495. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact